Abstract
Second-Line Ponatinib in Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients Failing or Intolerant to First-Line Second Generation Tyrosine Kinase Inhibitor (TKI) Treatment: An Interim Analysis of the Prospective PONS Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have